Kinetic Partners Management LP Makes New Investment in Natera, Inc. $NTRA

Kinetic Partners Management LP purchased a new stake in Natera, Inc. (NASDAQ:NTRA - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 60,800 shares of the medical research company's stock, valued at approximately $16,504,000.

A number of other hedge funds have also modified their holdings of the company. Trust Co. of Vermont bought a new position in Natera in the second quarter valued at approximately $26,000. Reflection Asset Management acquired a new position in shares of Natera during the 4th quarter worth approximately $29,000. Elevation Wealth Partners LLC bought a new stake in Natera during the second quarter worth $30,000. Palladiem LLC bought a new stake in shares of Natera in the 4th quarter valued at about $31,000. Finally, Horizon Investments LLC acquired a new stake in shares of Natera in the third quarter valued at approximately $32,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Canaccord Genuity Group set a $375.00 target price on shares of Natera in a research note on Friday, August 7th. TD Cowen increased their price target on shares of Natera from $325.00 to $340.00 and gave the company a "buy" rating in a report on Friday, August 7th. Piper Sandler raised their price objective on shares of Natera from $249.00 to $363.50 and gave the stock an "overweight" rating in a research report on Wednesday, August 12th. Royal Bank Of Canada boosted their price objective on Natera from $275.00 to $350.00 and gave the stock an "outperform" rating in a report on Friday, August 7th. Finally, Guggenheim increased their target price on Natera from $290.00 to $360.00 and gave the stock a "buy" rating in a research note on Wednesday, August 12th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Natera currently has an average rating of "Moderate Buy" and an average price target of $319.38.

Natera Stock Up 2.7%

NASDAQ:NTRA opened at $336.71 on Wednesday. The firm has a market capitalization of $48.53 billion, a PE ratio of -247.58 and a beta of 1.51. Natera, Inc. has a twelve month low of $157.43 and a twelve month high of $337.12. The stock's 50-day simple moving average is $278.79 and its 200 day simple moving average is $231.01.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. The company had revenue of $752.75 million during the quarter, compared to analysts' expectations of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.Natera's revenue was up 37.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.74) EPS. On average, analysts anticipate that Natera, Inc. will post -1.02 EPS for the current fiscal year.

Insider Activity at Natera

In related news, Director Roelof Botha sold 78,000 shares of the business's stock in a transaction on Monday, June 1st. The shares were sold at an average price of $220.31, for a total value of $17,184,180.00. Following the transaction, the director owned 1,076,198 shares in the company, valued at $237,097,181.38. The trade was a 6.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Solomon Moshkevich sold 3,410 shares of the firm's stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $265.58, for a total value of $905,627.80. Following the sale, the insider directly owned 129,019 shares of the company's stock, valued at $34,264,866.02. This represents a 2.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 177,955 shares of company stock valued at $40,704,193 over the last ninety days. Insiders own 5.05% of the company's stock.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source